The Food and Drug Administration on Tuesday released a warning letter that it sent to medical device company Dexcom on March 4 citing quality issues at the facilities responsible for testing its ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...

DexCom DXCM-1.14%decrease; red down pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

If you want to stay updated on the latest options trades for DexCom, Benzinga Pro gives you real-time options trades alerts.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025.

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous glucose monitor maker’s facilities last year. In a filing with the ...

Eligible residents living with diabetes in Saskatchewan who rely on any type of insulin may be eligible to receive coverage ...

DexCom, Inc. (NASDAQ:DXCM – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the eighteen ratings firms that are covering the firm, MarketBeat Ratings reports.

DexCom recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact its ability ...